ASN Kidney Week 2026: Emerging Nephrology Trends
ASN Kidney Week at a glance ASN Kidney Week 2026 highlights emerging…
ACTRIMS–ECTRIMS 2026 Preview: Multiple Sclerosis Therapies and AI
ACTRIMS–ECTRIMS 2026 at a glance The joint ACTRIMS–ECTRIMS 2026 meeting in…
ERA 2026 Preview: Competitive Shifts in Nephrology
ERA 2026 at a glance ERA 2026 highlights emerging competitive developments in…
Lucid Diligence Brief: R1 Therapeutics $77.5 million Series A to treat hyperphosphatemia in CKD dialysis
Lucid Diligence Brief: R1 Therapeutics $77.5 million Series A to treat…
Health Mobile Apps Landscape in H2 2025
Trending in Health Mobile Apps: Current Trends, Rankings and Insights from H2…
Lucid Diligence Brief: Rectify and Boehringer Ingelheim partnership in CKD
Lucid Diligence Brief: Rectify and Boehringer Ingelheim partnership in CKD…
Lucid Diligence Brief: Insilico-TaiGen CKD anemia licensing deal
Lucid Diligence Brief: Insilico-TaiGen CKD anemia licensing deal Professional…
Lucid Diligence Brief: SanegeneBio RNAi $110 million Series B
Lucid Diligence Brief: SanegeneBio RNAi $110 million Series B Professional…
AUA 2025 Preview: Key Highlights in Urology to Watch
AUA 2025 at a glance Ahead of AUA 2025, explore LucidQuest’s succinct…